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Abstract
Background: Successful antiretroviral treatment is dependent on sustaining high rates of adherence. In the
southern African context, only a handful of studies (both quantitative and qualitative) have looked at the
determinants including a health behaviour theory of adherence to antiretroviral therapy. The aim of this study is to
assess factors including the information, motivation and behavioural skills model (IMB) contributing to antiretroviral
(ARV) adherence six months after commencing ARVs at three public hospitals in KwaZulu-Natal, South Africa.
Methods: Using systematic sampling, 735 HIV-positive patients were selected prior to commencing on ART from
outpatient departments from three hospitals and followed-up at six months and interviewed with a questionnaire.
Results: A good proportion of patients were found to be adherent using both adherence instruments (visual
analog scale = VAS 82.9%; Adult AIDS Clinical Trials Group = AATCG 70.8%). After adjusting for significant socio-
economic variables, both the VAS and the dose, schedule and food adherence indicator found levels of adherence
amongst urban residents to be almost 3 times greater than that of rural residents. After adjusting for health-related
variables, for both indicators better adherence was associated with low depression and poorer adherence was
associated with poor environmental factors. Adjusted odds ratios for adherence when taking into account different
behavioural variables were for both adherence indicators, discrimination experiences were associated with lower
adherence, and higher scores in adherence information and behavioural skills were associated with higher
adherence. For the VAS adherence indicator, higher social support scores were associated with higher adherence.
For the dose, schedule and food adherence indicator, using herbal medicines for HIV was associated with lower
adherence.
Conclusion: For the patients in this study, particularly those not living in urban areas, additional support may be
needed to ensure patients are able to attend appointments or obtain their medications more easily. Adherence
information and behavioural skills as part of the IMB model should be strengthened to improve adherence. Further
psychological support is also required and patients’ perceived need for ARTs should be routinely assessed.
Background
The clinical efficacy of antiretroviral therapies (ART) in
suppressing the HIV virus and improving survival rates
for those living with HIV has been well documented
[1-5]. However, successful antiretroviral treatment is
dependent on sustaining high rates of adherence (cor-
rect dosage, taken on time and in the correct way -
either with or without food). The minimum level of
adherence required for antiretrovirals (ARVs) to work
effectively is 95% [6]. Although more potent ARV regi-
mens can allow for effective viral suppression at
moderate levels of adherence [7-9], non or partial adher-
ence can lead to the development of drug-resistant
strains of the virus. In resource-limited settings where
older first-line therapies are being used, the develop-
ment and transmission of drug-resistant strains of HIV
will greatly limit the treatment options available.
A meta-analysis conducted by Mills et al. [10], exam-
ined barriers and facilitators of ART adherence in 72
developed and 12 developing country settings (5 Afri-
can). Barriers to adherence in both settings included
fear of disclosure, forgetfulness, health illiteracy, sub-
stance abuse, complicated regimens, and patients being
away from their medications. In developing settings,
financial constraints and a disruption in access to
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medications were also common barriers. Other factors
known to affect adherence include issues related to gen-
der [11,12] and stigma [13-15]. In the southern African
context, only a handful of studies (both quantitative and
qualitative) have looked at the determinants of adher-
ence to antiretroviral therapy. Common barriers identi-
fied include fear of disclosure, alcohol use, traditional
medicine use, feeling better on treatment, inadequate
knowledge about the disease and ARVs, stigma, trans-
port costs, [16-20], lack of social support (financial and
emotional) [17], stigma, discrimination, depression and
hopelessness, not being able to disclose their HIV status
and a lack of food [19,20], service-related factors
[18,20], patients’ beliefs and behaviours [18], pill burden
and drug side-effects [18,20].
There is a lack of studies investigating treatment com-
petency factors and also utilizing a health behaviour the-
ory such as the Health Belief Model [18] in relation to
ART adherence in Africa [21]. One promising health
behaviour theory that has been tailored specifically to
designing interventions to promote adherence to ART
in developed countries is the information, motivation
and behavioural skills model (IMB) [22]. The aim of this
study is to assess factors including the information,
motivation and behavioural skills model (IMB) contri-
buting to ARV adherence six months after commencing
ARVs at three public hospitals in KwaZulu-Natal, South
Africa.
Methods
Design and setting
This is a cross-sectional study of all treatment-naúve
patients (N = 735) recruited from all three public hospi-
tals in Uthukela health district in KwaZulu-Natal from
October 2007 to February 2008. The District has one
regional and two district hospitals, one private hospital,
three primary health care facilities, 24 fixed clinics and
17 mobile clinics with 177 visiting points [23]. Initiation
to ART is done at the three public hospitals. Some
patients are referred to primary care clinics for ARV
collection but return to the hospital for six monthly vis-
its. HIV treatment is provided free of charge. The treat-
ment programme provides patients with access to
counselling, nutritional assistance, psychosocial support
and social welfare evaluation.
Sample and procedure
All ARV-naúve patients who were about to commence
ARVs (18 years and above) and who consecutively
attended the HIV clinics during the recruitment period
were eligible for this study. Physicians from the three
selected public clinics asked every consecutively visiting
ART-naïve patient meeting the inclusion criteria of
being 18 years or over if they would like to complete a
confidential survey and interview concerning their
health and social situation. This would include informa-
tion from their medical records on details of their medi-
cal condition, laboratory tests and treatment. If the
potential participant indicated an interest in participat-
ing, the health care provider then referred them to an
external HSRC research assistant for possible research
participation. The interviews were conducted by four
trained external HSRC researchers (one or two per HIV
clinic) in interview administration of the semi-structure
interview schedule. Interviewers were trained over one
week in questionnaire administration and ethics proce-
dures. Recruitment took place over a period of four
months, with 97.8% participation rate. The questionnaire
was translated into the major language spoken in the
study area (Zulu) and verified by a second translator.
Where inconsistencies were found, these were corrected.
Pre-testing of the questionnaire was completed with five
HIV-positive persons not involved in the study. More
details about the setting, sampling procedure and
recruitment have been described elsewhere [24]. Patients
at six months follow-up were interviewed at the clinic.
Patients who failed to attend for planned follow-up were
contacted by telephone and up to two home visits.
Ethics approval was obtained from the HSRC ethics
committee and approval was obtained from the Provin-
cial Department of Health in KwaZulu-Natal.
Measures
Patients were interviewed with an anonymous question-
naire that requests information on sociodemographic
characteristics, clinical history and health-related charac-
teristics and health beliefs. Clinical data relating to date
of HIV diagnosis, HIV acquisition and transmission risk
factors, current CD4 cell count, viral load (Chiron 3.0
bDNA), opportunistic infections, HIV and non-HIV
medications was obtained from the medical chart.
The Revised Sign and Symptom Checklist for Persons with
HIV Disease
The SSC-HIVrev is a 72-item checklist of HIV/AIDS
specific physical and psychological symptoms, scored
using the following scale: 0 = not present today, 1 =
mild, 2 = moderate, 3 = severe [25]. Female-specific
symptoms were removed, reducing the total to 64 [24].
An HIV symptom index (symptom intensity) was cre-
ated which weights each symptom’s presence (0 or 1) by
a rating of 1-3 (mild, moderate or severe). Cronbach’s
alpha of this scale for this sample was 0.84.
Health-Related Quality of Life
The WHOQOL-HIV BREF is based on the WHOQOL-
HIV measure, one of the two World Health Organiza-
tion’s QoL instruments for use with HIV-infected
populations [26]. This instrument is intended for cross-
cultural use and is meant to be accessible to researchers
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in low-income countries. The individual respondent’s
overall QoL are measured directly: ‘How would you rate
your quality of life?’ (ranging from ‘very poor’ to ‘very
good’); ‘How satisfied are you with your health?’
(ranging from ‘very dissatisfied’ to ‘very satisfied’). The
31-item WHOQOLHIV BREF produces six domain
scores, which denote an individual’s subjective percep-
tion of their own QoL in the following domains: physi-
cal, psychological, level of independence, social
relationships, physical environment and spirituality. The
individual items are rated on a 5-point Likert scale
where ‘1’ indicates ‘low, negative perceptions’ and ‘5’
indicates ‘high, positive perceptions.’ Domain scores are
scaled in a positive direction, where higher scores
denote higher perceived QoL [27]. Reliability was good
for five of the six domains (Cronbach’s alpha 0.60-0.72)
and lower for the social relationships domain (Cron-
bach’s alpha 0.46). Cronbach’s alpha for the whole
HRQoL scale was 0.88 for this sample.
Alcohol Use Disorder
Identification Test (AUDIT)-C focuses solely upon con-
sumption of alcohol (i.e. the frequency of drinking, the
quantity consumed at a typical occasion, and the fre-
quency of heavy episodic drinking (i.e. consumption of
six standard drinks or more on a single occasion - in
South Africa a standard drink is 12 g alcohol) [28].
Because AUDIT is reported to be less sensitive at identi-
fying risk drinking in women [29], the cut-off points of
binge drinking for women were reduced by one unit as
compared with men. Gual et al. [30] recommend a cut-
off point of ≥ 5 for men and ≥ 4 for women although
the false-positive rate was 46.5% among male and 63.3%
among female patients when compared with a clinical
diagnosis of risky drinking. Cronbach’s alpha for the
AUDIT-C in this sample was 0.85.
Internalized AIDS stigma
Items were adapted to assess internalized AIDS stigma
from a scale developed to measure AIDS related stigma
beliefs in general South African populations. We
selected seven items from the AIDS-Related Stigma
Scale [31] and reframed the wording to represent nega-
tive self-perceptions and self-abasement in relation to
being a person living with HIV/AIDS. The items
focused on self-blame (e.g., “I sometimes feel worthless
because I am HIV positive.”) and concealment of HIV
status from others (e.g., “I hide my HIV status from
others.”). In this study, we examined responses to each
of the four internalized stigma items as individual indi-
cators of internalized AIDS stigma and we computed a
scale by summing all items endorsed in the direction of
greater internalized stigma. Items were responded to
from 1 = strongly agree to 4 = strongly disagree.
Strongly agree and agree were converted to “1” and
strongly disagree and disagree to “0"; scale scores
represent the sum total of endorsed items, range 0-7.
Cronbach’s alpha for this stigma index was 0.64 for this
sample.
HIV/AIDS discrimination experiences
To assess AIDS-related discrimination, we asked partici-
pants if they had experienced seven discrimination-related
events, e.g., whether they had been treated differently
since they had disclosed their HIV status to friends and
family; whether being HIV positive had caused them to
lose a job or a place to stay; and whether they had experi-
enced discrimination because they are HIV positive.
Response options were “yes” or “no”. Cronbach’s alpha for
this sample was 0.54.
Social support
Three items were drawn from the Social Support Ques-
tionnaire to assess perceived social support [32]. The
items were selected to reflect perceived tangible and
emotional support: If I were sick and needed someone
to take me to a doctor I would have trouble finding
someone (reversed); I feel that there is no one I can
share my most private concerns and fears (reversed);
and I feel a strong emotional bond with at least one
other person. These items were responded to on 4-point
scales, 1 = completely true, to 4 = completely false, and
summed to a score with a range of 3-12. Cronbach’s
alpha for this sample was .83.
We assessed depressive symptoms using the 10-item
version of the Centers for Epidemiologic Studies
Depression Scale (CES-D) [33]. The CES-D has been
widely used in studies of the relationship between HIV
and depression [34]. Cronbach’s alpha for this sample
was 0.54.
Adherence assessment
ARV treatment adherence was assessed by two self-
reported adherence measures - the Adult AIDS Clinical
Trials Group (AACTG) adherence instrument and the
30-day visual analog scale (VAS). The AACTG consists
of nine questions that assess adherence from the previous
1-4 days, within the past week, prior to the interview.
The instrument also assesses reasons for non-adherence
[35]. The 30-day visual analog scale (VAS) provided an
overall adherence assessment for a longer time interval
(one month). Both have been validated in resource-lim-
ited settings [36,37]. Adherence is calculated as the % of
doses taken over those prescribed. Adherence levels
assessed from the VAS are defined as follows: full adher-
ence = 100%, partial adherence >/= 95% and < 100%, and
non-adherence as < 95% of prescribed doses taken since
the last refill.
Dose adherence was assessed by asking participants to
report on how many days they had missed taking all
their doses during the past 4 days. Dose non-adherence
was defined as having missed all doses on at least one
day during the past 4 days.
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Adherence to scheduling was measured by the ques-
tion “Most anti-HIV medications need to be taken on a
schedule, such as ‘2 times a day’ or ‘3 times a day’ or
‘every 8 hours.’ The participants were asked to report
how closely they followed their specific schedule over
the last 4 days using a 5-point Likert scale, ranging from
“never” to “all the time.” Schedule non-adherence was
defined as having missed scheduling in the past 4 days.
Adherence to dietary instructions was measured by first
asking “Do any of your anti-HIV medications have
special food instructions, such as ‘take with food’ or ‘on
an empty stomach’ or ‘with plenty of fluids’?” If the
response was “yes,” participants were asked to rate how
often they had followed dietary instructions over the last
4 days using a 5-point Likert scale, ranging from never”
to “all the time.” Schedule non-adherence was defined
as having missed scheduling in the past 4 days. Food
non-adherence was defined as not having followed
special instructions over the last 4 days.
The LifeWindows Information-Motivation-Behavioural
Skills ART adherence questionnaire (LW-IMB-AAQ)
[38,39]. Each LW-IMB-AAQ item represents a barrier
primarily falling within the I (Information), M (Motiva-
tion), or B (Behavioural Skills) constructs. Adherence
information was assessed with five items (a .69). Exam-
ple for an information item: “I know what to do if I
miss a dose of any of my HIV medications (for example,
whether or not to take the pill(s) late).” Responses to
items include “yes,” “no,” or “don’t know” ("don’t know”
responses were keyed as incorrect responses). Adher-
ence motivation was assessed with ten items (a .78).
A “motivation” sample item: “I am worried that other
people might realize that I am HIV+ if they see me tak-
ing my HIV medications.” Response options were 1 =
strongly disagree to 5 = strongly agree. Behavioural skills
were assessed with 14 items (a .73). An example of a
behavioural skills item: “How hard or easy is it for you
to stay informed about HIV treatment?” Response
options were 1 = cannot do at all to 5 = certain you
can do.
Data analysis
Data were analyzed using Statistical Package for the
Social Sciences (SPSS) for Windows software application
programme version 17.0. Frequencies, means, standard
deviations, median, interquartile range, were calculated
to describe the sample. Uni- and bi-variate analyses and,
multiple logistic regressions were used to investigate
associations between the outcomes ART adherence and
socioeconomic variables, health related variables, and
behavioural variables as well as information-mativation-
behavioural skills model variables. Associations were
considered significant at P < 0.05. Separate multivariable
logistic regression analyses were conducted for socio-
demographic variables, health related variables and
behavioural variables (moderating factors) and informa-
tion-mativation-behavioural skills model variables and
ART adherence. All variables statistically significant at
the P < .01 level in bivariate analyses were included in
the multivariate model. No significant interactions were
found between socioeconomic variables, health related
variables, behavioural variables and information-mativa-
tion-behavioural skills model variables.
Results
Sample characteristics
Of 735 patients (29.8% male and 70.2% female) who
completed assessments prior to initiation of ARVs, 525
were able to complete the assessment at six months fol-
low-up. Of the original cohort, 75 had died, 57 had
been transferred, 54 could not be traced, 23 refused the
interview and 1 interview was incomplete. At six
months following proposed ARV initiation, 519 patients
started therapy and six failed to start treatment. Over
the six month period 24 patients (4.6%) had temporarily
suspended ARVs because of side effects, and three
(0.6%) had changed their ARVs. HIV medications for
411 (79.2%) patients included Lamivudine (3TC), Stavu-
dine (d4T) + Efavirenz (Stocrin) and for 108 (20.8%)
Lamivudine (3TC), Stavudine (d4T) + Nevirapine. Fixed
dose combination of ARVs was not available for patients
on this programme during the time of the study.
Nearly three-quarters (73.5%) of the 519 patients who
had initiated ARVs in this sample were female, 62.2% of
whom were between 30 and 49 years old. Nearly three-
quarters (73.3%) were never married, 61.9% had Grade 8
or higher formal education, almost all (98.8%) were
Zulu and the largest religious affiliation was charismatic
churches (38.5%). The majority of the sample (61.7%)
lived in rural areas and was unemployed (59.6%). Only
31.7% of respondents had a formal salary as their main
source of household income and 52.5% was in receipt of
a disability grant. Those who were followed up at six
months (n = 525) were compared to those who could
not be followed up (n = 210) on sex, age, formal educa-
tion, urban or rural residence, HIV symptoms, CD4 cell
count and in recept of a disability grant. We found that
those who could not be followed up were more likely to
be male (c2 = 8.13, P = .004) and had a lower CD4 cell
count (t = -2.55, p = .011) (v. Table 1).
Health characteristics
Most patients (75.2%) had been diagnosed with HIV in
the year prior to study recruitment. The median CD4
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count at follow-up was 130 cells/cu.mm compared to
119 cells/cu.mm prior to ARV initiation. The mean
number of HIV symptoms reported at follow-up was
1.21, 6.6% of patients were receiving TB treatment,
10.3% had at least one hospital admission in the past six
months, and 25.6% had seen an ARV treatment buddy
at least once in the past six months. Patients with an
identified adherence problem are referred to a treatment
buddy (v. Table 2).
ART adherence
Using the 30-day visual analog scale (VAS) 427 patients
(82.9%) were 95% adherent in the month prior to the
survey. Results from the AACTG adherence instrument
found that on the 4-day recall dose adherence, 15.5% of
patients were non-adherent (having missed at least one
full day of medication in the past four days). 70.8% of
patients were adherent to all parameters (dose, schedule
and food). Pearson correlation among the two adherence
outcome measures (VAS and AACTG) using categorical
cutoffs to define adherence indicated a moderate level of
association (r = .56, P < .001). From those found non-
adherent on the VAS (17.1%) 85.2% were also found to
be non-adherent on the AACTG measure (v. Table 3).
Determinants of ART adherence
Both the VAS and the dose, schedule and food adher-
ence indicator found levels of adherence amongst
urban residents to be almost 3 times greater than that
of rural residents. The VAS indicator found greater
adherence amongst those with lower levels of educa-
tion and amongst single, separated, divorced or
widowed groups compared to those married and coha-
biting (v. Table 4).
After adjusting for health-related variables, for both
indicators adherence was lower amongst those with
higher depression scores and for those with low scores
in the Environment domain (safety/healthy physical
environment/enough money/access to information/
opportunity for leisure activities/transport/access to
health services). The dose, schedule and food adherence
indicator found adherence to be 3.3 times greater
amongst patients with a CD4 count above 200 cells/uL,
4.6 times greater among patients with the 3TC, d4T +
Nevirapine regimen and higher overall quality of life.
The VAS adherence indicator found higher adherence
amongst patients with lower scores in the Spirituality/
religion/personal beliefs domain, with higher general
health perception scores and with higher scores in social
relationships domain (v. Table 5).
Table 6 presents crude and adjusted odds ratios for
adherence when taking into account different beha-
vioural variables (moderating) factors and informa-
tion-motivation-behavioural skills model variables. For
Table 1 Sample characteristics
Variable N = 519 %
Sex
Male 139 26.6
Female 370 73.4
Age in years 136 26.3
18-29 222 42.9
30-39 100 19.3
40-49 59 11.4
50 and above
Marital status
Never married 379 73.3
Currently married 68 13.2
Cohabitating 40 7.7
Divorced/separated 11 2.2
Widowed 19 3.7
Highest education
None 40 7.7
Up to Grade 7 157 30.4
Grade 8-11 221 42.7
Grade 12 or more 99 19.1
Ethnicity
Zulu 513 98.8
Other 6 1.2
Religious affiliation
African/traditional 52 10.0
Christian (Protestant churches) 73 14.1
Christian (Catholic) 49 9.4
Apostolic 48 9.2
Zion Christian Church 152 29.3
Other 71 14.0
No religion 74 14.3
Residence
Rural village 221 42.7
Informal settlements (slums) 31 6.0
Urban/metropolitan areas 49 9.5
Township 118 22.8
Farm 98 19.0
Employment situation
Housewife, home maker 76 15.0
Unemployed 303 59.6
Employed 115 22.6
Pensioner, student, disabled 21 4.2
Main source of household income
Formal salary 162 31.7
Contribution by family members 86 16.9
Government grant 113 22.1
Grants/donations by private welfare organizations 80 15.7
No income (other than social grant) 38 7.4
Other 32 6.3
Disability grant ("for HIV/AIDS”)
Yes 268 52.5
No 242 47.5
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both adherence indicators, discrimination experiences
were associated with lower adherence, and higher
scores in adherence information and behavioural skills
were associated with higher adherence. For the VAS
adherence indicator, higher social support scores were
associated with higher adherence. For the dose, sche-
dule and food adherence indicator, using herbal medi-
cines for HIV was associated with lower adherence
(v. Table 6).
Discussion
A good proportion of patients were found to be adher-
ent using both adherence instruments (VAS 82.9%;
AATCG 70.8%). These good figures are similar to that
of 77% found for African patients the meta-analysis by
Mills and colleagues [40]. Such good rates may however
decline the longer patients are on treatment. Kalichman
et al. [41] found that the VAS yielded adherence rates
that paralleled unannounced pill counts and differed
from AATCG recall suggesting that the VAS offers a
valid method of assessing medication adherence. How-
ever, the combined dose, schedule and food adherence
indicator of the AATCG may be useful in identifying
schedule and food adherence, and found in this study
different adherence rates and influencing factors as
compared to the VAS. For example, lower dose, sche-
dule and food adherence was found for patients on
3TC, d4T + Efavirenz regimen and those who were
taking herbal medicine for HIV.
Important socio-economic predictors of ART adher-
ence in this South African sample include urban area of
residence and adequate physical environment including
transport and access to health services. Living in an
urban area is likely to be associated with lower transport
costs and fewer disruptions in access to medications,
which other studies have found to be a facilitators of
adherence [11,18,20].
Table 2 Health and behavioral characteristics
Variable N = 519 %
Time since HIV diagnosis
2007/8 379 75.2
2006-1995 125 24.8
CD4 count (cells/uL) = Median = 130 (IQR = 72-185) (at baseline: Median = 119; IQR = 59-163)
1-99 188 37.2
100-200 232 45.9
>200 85 16.8
Number of HIV symptoms (range 0-20) M(SD) 1.21 (2.60)
Overall Quality of Life (range 1-5) M(SD) 4.3 (0.7)
General health perceptions (range 1-5) M(SD) 4.4(0.7)
Depression score (range 10-40) M(SD) 17.3(3.3)
Receiving TB treatment 34 6.6
Hospital admission in the past 6 months 53 10.3
Participated in support group in the past 6 months 14 2.7
Seen someone for counseling/support in the past 6 months 123 23.8
Seen an ARV treatment buddy in the past 6 months 132* 25.6
Had alcohol in the past month 13 2.5
AUDIT-C 4 or more 10 1.9
Stigma score (range 0-7) M(SD) 2.8 (1.8)
Discrimination experience score (range 0-5) M(SD) 0.87 (1.11)
Social support score (range 3-12) M(SD) 8.3 (2.3)
*Of those who saw a treatment buddy, 93% saw a buddy only once in the past 6 months
Table 3 ART adherence
n %
30-day VAS at 95% Adherent 427 82.9
Non-adherent 88 17.1
Self-reported 4-day recall dose adherence Adherent 435 84.5
Non-adherent 80 15.5
Self-reported time adherence Adherent 372 72.4
Non-adherent 142 27.6
Self-reported food adherence Adherent 369 71.7
Non-adherent 146 28.3
Adherence to all (Dose, Schedule and Food) Adherent 364 70.8
Non-adherent 150 29.2
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For health-related variables in this sample, lower
depression scores were significantly associated with
higher adherence for both adherence indicators. Other
studies have similarly found that psychological health
[11,20] is an important facilitator of adherence. Patients
who had a CD4 count greater than 200 cells/uL, higher
environment domain scores and better general health
perception and overall quality of life scores reported
higher adherence at their 6 month follow up. In a recent
South African study, Wouters, Van Dammeb and Van
Loon [42] found that baseline health (CD4 count) signif-
icantly influenced treatment outcomes during the first
6 months of ART. Patients with higher CD4 counts and
better perceptions of their health are likely to have wit-
nessed greater improvements in their health as a result
of commencing ART. As Mills and colleagues meta-ana-
lysis indicates, this is likely to facilitate adherence.
Whilst the use of prayer predicted higher adherence in
a Zambian study [20], the use of prayer was not asso-
ciated with levels of adherence in the present study and
was therefore excluded from analysis. The ‘spirituality/
religion/personal beliefs’ domain contains items about
whether the respondent considers their life to be mean-
ingful, to what extent they are bothered about others
blaming them for their illness, whether they fear for the
future or worry about death and dying because of HIV.
Higher scores (more positive attitudes about life and
fewer worries about dying) in this domain were asso-
ciated with lower adherence. These patients may have a
lower perceived need for ART than other patients.
Behavioural variables associated with greater adher-
ence include, high scores for IMB adherence informa-
tion and behavioural skills and not using herbal
medicines. Having greater knowledge about HIV and
ARVs and greater HIV treatment behavioural skills and
not using herbal medicines are known facilitators of
adherence and confirm the IMB mdel [17-20,40].
Equally, higher social support scores and experiencing
less discrimination were predictors of higher adherence
in this study. Further research is needed to identify risk
factors and to improve retention thorugh the use of
social networks or emerging technologies for patients at
risk for poor adherence [43].
Limitations
This study also has limitations. For more than 95% of
the patients studied viral loads were not available from
medical records; they had not been done. So an impor-
tant outcome of ART and ART adherence viral suppres-
sion could not be assessed. The patients who died or
were lost to follow-up in the first 6 months were not
included in the present study (selection bias). Some
Table 4 Association between socioeconomic variables and ART adherence
VAS adherence (≥ 95%) Dose, schedule and food adherence
N = 519 (%) Crude OR
(95% CI)
P Crude OR
(95% CI)
P
Sex
Female 370 (26.6) 1.00 1.00
Male 139 (73.4) 1.08 (0.54-1.56) .747 1.03 (0.63-1.50) .887
Age 0.99 (0.97-1.02) .673 1.01 (0.99-1.03) .615
Formal education
lower (up to Grade 7) 197 (38.1) 1.00 1.00
higher (Grade 8 or more) 320 (61.9) 0.89 (0.81-1.00) .050 0.99 (0.91-1.08) .895
Marital status
Married/cohabitating 108 (20.9) 1.00 1.00
Single/separated/divorced/widowed 409 (79.2) 1.79 (1.02-3.00) .028 0.99 (0.62-1.59) .974
Employment status
Unemployed 393 (77.4) 1.00 1.00
Employed 115 (22.6) 1.00 (0.58-1.74) .991 1.23 (0.77-1.97) .386
On disability grant ("for AIDS”)
No 242 (47.5) 1.00 1.00
Yes 268 (52.5) 1.09 (0.69-1.72) .722 0.91 (0.62-1.34) .642
Residence
Rural 319 (61.7) 1.00 1.00
Urbanct 198 (38.3) 2.78 (1.60-4.83) .000 3.34 (2.13-5.25) .000
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factors such as food insecurity, transportation barriers,
and structural barriers of ARV adherence were not
assessed [40]. Further, the assessment of ART adherence
and other measures relied on self-report. However, there
is increasing evidence indicating that adherence is reli-
ably reported [41,44]. Caution is also urged in generaliz-
ing findings to other districts and provinces in the
country. Investigation of factors related with long-term
adherence would require longer follow-up than the
current study.
Conclusions
The adherence rate found in this study seems to be
good. The use of two different adherence indicators
was important for reducing bias through self-reporting
and therefore enabling a greater potential range of
determinants to be identified. Given the sample size
and the large number of potential determinants of
adherence in this study, variables were analysed in par-
simonious subsets rather than one model. For the
patients in this study, particularly those not living in
urban areas, additional support may be needed to
ensure patients are able to attend appointments or
obtain their medications more easily. Adherence infor-
mation and behavioural skills as part of the IMB
model should be strengthened to improve adherence.
Further psychological support is also required and
patients’ perceived need for ARTs should be routinely
assessed. Although caution is urged in generalizing
findings to other districts and provinces in the country,
the results generally support the findings from other
adherence studies in southern Africa.
Table 5 Association between health-related variables and ART adherence
VAS adherence (≥ 95%) Dose, schedule and food adherence
N (%)
519
Crude OR
(95% CI)
P Adjusted
ORa, b
(95% CI)
P Crude OR
(95% CI)
P Adjusted ORa, c
(95% CI)
P
Time since diagnosis
2006-1995 125 (24.8) 1.00 1.00
2007/8 379 (75.2) 0.49 (0.26-0.92) .026 ... 0.80 (0.50-1.26) .330 —
Hospital admission in the past 6 months
No 463 (89.7) 1.00 1.00
Yes 53 (10.3) 1.51 (0.62-3.69) .326 ... 0.98 (0.51-1.85) .937 —
CD4 count
≤ 200 420 (83.2) 1.00 ... 1.00 1.00
>200 85 (16.8) 1.19 (0.63-2.26) .599 2.90 (1.52-5.53) .001 3.32 (1.18-9.38) .023
HIV symptoms (range 0-20)
M (SD) 1.2 (2.6) 1.08 (0.96-1.21) .213 ... 1.06 (0.97-1.15) .199 —
Overall Quality of Lifed
M (SD) 4.3 (0.7) 2.87 (2.00-4.10) .000 0.94 (0.52-1.68) .830 3.91 (2.71-5.65) .000 2.06 (1.07-3.98) .031
General health perceptionsd
M (SD) 4.4 (0.7) 2.69 (1.95-3.73) .000 1.72 (1.01-2.95) .047 3.72 (2.62-5.28) .000 1.57 (0.89-2.79) .121
WHOQOL-HIV BREFscores
Physical domaine 15.6 (2.7) 1.35 (1.22-1.49) .000 0.94 (0.78-1.13) .512 1.54 (1.40-1.69) .000 0.87 (0.70-1.08) .201
Psychological domaine 14.6 (3.2) 1.40 (1.28-1.53) .000 1.17 (0.97-1.41) .099 1.65 (1.50-1.81) .000 1.00 (0.81-1.23) .970
Level of independence domaine 14.5 (1.9) 1.42 (1.29-1.56) .080 ... 1.10 (0.98-1.24) .103 ...
Social relationships domaine 13.4 (2.6) 1.52 (1.37-1.69) .000 1.14 (1.00-1.30) .048 1.65 (1.49-1.83) .000 1.05 (0.89-1.24) .549
Environment domaine 13.9 (2.6) 1.76 (1.56-2.00) .000 1.56 (1.28-1.89) .000 2.46 (2.11-2.87) .000 2.21 (1.71-2.86) .000
Spirituality/religion/personal beliefs domaine 15.3 (2.9) 1.17 (1.08-1.27) .000 0.76 (0.63-0.91) .003 1.40 (1.29-1.51) .000 1.06 (0.89-1.28) .507
Depression score (higher score = more
depressed)
17.3 (3.3) 0.78 (0.72-0.84) .000 0.88 (0.80-0.96) .006 0.63 (0.58-0.69) .000 0.71 (0.62-0.80) .000
ART regimen
3TC, d4T + Efavirenz 411 (79.2) 1.00 1.00 1.00 1.00
3TC, d4T + Nevirapine 108 (20.8) 4.08 (1.73-9.63) .001 2.16 (0.80-5.87) .130 5.25 (2.57-
10.72)
.000 4.61 (1.48-14.34) .008
aUsing block entry;bHosmer and Lemeshow Chi-square = 11.67, df = 8, p = .166; bCox & Snell R2 .26; b Nagelkerke R2 .42;
cHosmer and Lemeshow Chisquare = 25.05, df = 8, p.002; cCox & Snell R2 .54; c Nagelkerke R2 .76
d Mean scores range from 1 to 5, with 5 indicating the highest, most positive perceptions of quality of life or general health perceptions.
e Overall domain scores range from 4 to 20, with 20 indicating the highest, most positive perceptions.
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